tbuckley/cabot-search huggingface dataset:
Clinical significance of sunitinib-associated macrocytosis in metastatic renal cell carcinoma.
Authors: Maria Teresa Bourlon, Dexiang Gao, Sara Trigero, Julia Elizabeth Clemons, Elaine Tat Lam, Thomas W. Flaig
Journal: Journal of Clinical Oncology (2015)

453 Background: Increases in mean corpuscular volume (MCV) and hypothyroidism have been observed in patients on sunitinib treatment. We characterized tyrosine kinase-associated macrocytosis in metastatic renal cell carcinoma (mRCC) patients and its relationship, along with thyroid dysfunction, to progression-free survival (PFS). Methods: A retrospective chart review was performed on patients treated with sunitinib and/or sorafenib (01/2005-01/2011). Data pertaining to the development of macrocytosis was analyzed in association with our previous data on thyroid dysfunction in these patients. We assessed PFS, as clinically defined by the treating provider. Results: Seventy-four patients with 103 treatment periods for sorafenib (47) and sunitinib (56) were analyzed. Macrocytosis was found in 55% and 8% of sunitinib and sorafenib treatment periods, respectively (p&lt;0.001). Focusing on the sunitinib-treated patients for all further analysis, the median PFS was 11 months (mo) (95% CI, 6-19). Median PFS was 21 mo (95% CI, 11-25) for patients who developed macrocytosis compared to 4 mo (95% CI, 3-8) in normocytic patients (p=0.0001). The time to development of macrocytosis did not affect the degree of macrocytosis observed (p=0.47). Macrocytosis and hypothyroidism were both significant predictors of prolonged PFS in our cohort. The greatest difference in PFS was noted between patients who developed both macrocytosis and hypothyroidism (25 mo) versus those who remained both normocytic and euthyroid (5 mo) (p&lt;0.0001). Conclusions: Sunitinib-related macrocytosis is associated with a prolonged PFS in mRCC. The concurrent development of both hypothyroidism and macrocytosis in this setting was associated longer PFS compared to either alone. Increased MCV may be used as a biomarker for sunitinib response in this setting. [Table: see text]
Consensus development conference: coronary artery bypass grafting.
Journal: BMJ (1984)

Consensus development conference: coronary artery bypass grafting Britain's first consensus development conference was held in London from 21 to 23 November, sponsored by the King's Fund in association with the Royal College ofj Physicians and the Royal College of Surgeons.A panel oJ doctors and other professionals, including lawyers and economists, listened to expert evidence and debated it first in public and later in closed session.7he panel's report appears below (see leading article at p 14 7 7. Consensus statementCoronary artery disease is one of the major health problems in the Western world today.Coronary artery bypass surgery is a tech- nique in which a blocked or narrowed section of a coronary artery is bypassed using part of a vein or artery from elsewhere in the patient's body.The treatment has two separate objectives: the relief of angina and the prolongation of life.There are, however, alternative methods of treatment for coronary arterv disease, and there are a wide variety of views about which patients stand to benefit from coronary artery bypass surgery, especially in com- parison with these alternatives.Britain shares with Sweden, France, and Germany a rate of bypass operations per million population that is about one sixth of that in the United States, a quarter of that in Australia, and a third of that in Holland.Within the United Kingdom the rates over the five year period 1977-82 varied 10-fold among regions.These variations reflect differences in the availability of facilities for investigation and surgery and probably!also the differing views of doctors and patients about the indications for the procedure.A major questioin is whether there should be any change in the number of coronary artery bypass operations over the next few years, taking into account other demands on health care resources.Coronarv artery bypass surgery is only one aspect, albeit an important one, of the whole massive problem of coronary arteryThe panel comprised: 1rofessor
The effect of the proteosome inhibitor, PS 341 on leiomyosarcoma cells
Authors: G. Z. D’Amato, T. C. Windham, E. A. Keschman, S. Mohapatra, A. C. Burns, C. Muro-Cacho, R. Jove, D. Sullivan, G. D. Letson, W. J. Pledger
Journal: Journal of Clinical Oncology (2005)

9040 Background: Leiomyosarcomas (LMS) are one of the most common histologic types of soft tissue sarcoma and are usually resistant to standard chemotherapy. Bortezomib (PS 341) a reversible inhibitor of the 26S proteosome has been shown clinically to have anti-tumor activity in multiple myeloma and some solid tumors. To date there have been few studies using PS 341 in the treatment of LMS. We sought to investigate the effect of PS 341 on the leiomyosarcoma cell line SKLMS. Methods: Various doses of PS 341 were added to growing SKLMS and the untransformed human fibroblast cell line FLOW 2000. Cells were harvested at 24 and 48 hours and counted. Apoptosis was analyzed by both TUNEL and cleavage of PARP by Western blotting. Results: When treated with 50nm of PS 341 we observed decreased cell number at 24 hours in both FLOW 2000 and SKLMS cells, however at 48 hours no further reduction was seen in cell number for FLOW 2000 cells but SKLMS cell number continued to decline. Assessment of apoptosis demonstrated PARP cleavage of SKLMS cells at doses of 50nm and 100nm when analyzed at 24 and 48 hours. These observations were confirmed by TUNEL assay. Conclusions: Our results demonstrate that SKLMS cells undergo growth arrest, cell number reduction and apoptosis following treatment with PS 341. These results suggest that targeting proteosomes may be useful in the treatment of LMS. No significant financial relationships to disclose.
Assessing simple measures of patient-reported (PR) fatigue for oncology clinical trials: A pooled analysis of 3,915 patients
Authors: H. Liu, J. A. Sloan, D. J. Sargent, D. V. Satele, P. L. Schaefer, M. Y. Halyard, A. Grothey, Y. I. Garces, P. D. Brown, J. C. Buckner
Journal: Journal of Clinical Oncology (2009)

9563 Background: Fatigue is a prevalent and debilitating symptom reported by cancer patients (pts) which compromises a pt's quality of life (QOL). This study examined the relationship between PR fatigue and QOL as well as cancer-related symptoms (CRS) in 43 North Central Cancer Treatment Group and Mayo Clinic Cancer Center clinical trials. Methods: 3,915 pts from 43 oncology clinical trials provided baseline fatigue data on a single-item 0–100 point scale. Pts' QOL assessment included a single-item overall QOL and associated QOL domains measured by numerical analogues, the Profile of Mood States (POMS), and PR symptom assessment measures. Associations between fatigue and QOL domains were assessed by Spearman correlation coefficients. Wilcoxon rank sum test compared QOL scores between pts with clinically deficient fatigue(CDF, score ≤50) vs. no clinically deficient fatigue (nCDF, score&gt;50). Changes from baseline in fatigue and QOL were compared by Wilcoxon rank sum test with a 20-point change defined as clinically meaningful. Results: 38% of pts reported CDF at baseline and 45% of pts reported CDF at last assessment. Fatigue was only moderately correlated at best with overall QOL, pain, POMS, social and physical function (Spearman rho's of .27,.40, .56, .38 and .38 respectively). Pts with CDF averaged over 10 points lower overall QOL, pain, POMS, social, and physical function (see table below, all p&lt;.0001) as well as worsening CRS including sleepiness, nausea, headache, abnormal sweating, trouble sleeping, dry mouth, and sexual dysfunction (all p&lt;.001). Pts with 20+ points worsening in fatigue declined in overall QOL, physical function, pain and POMS (all p&lt;.0001). Conclusions: Patients with CDF suffer greater deficits in QOL and CRS. Patients report fatigue as distinctly different from overall QOL, pain, physical, social, mood status and CRS. Fatigue appears with a broad spectrum of CRS clusters. Routine measurement and management of fatigue could impact QOL and treatment-related symptoms. [Table: see text] No significant financial relationships to disclose.
Evidence for Extracellular Processing of Pro-von Willebrand Factor After Infusion in Animals With and Without Severe von Willebrand Disease
Authors: P.L. Turecek, L. Pichler, W. Auer, G. Eder, K. Varadi, A. Mitterer, W. Mundt, U. Schlokat, F. Dorner, L.O. Drouet, J. Roussi, J.A. van Mourik, H.P. Schwarz
Journal: Blood (1999)
Predictors of posttraumatic stress symptoms among survivors of the Oakland/Berkeley, Calif., firestorm
Authors: C Koopman, C Classen, D Spiegel
Journal: American Journal of Psychiatry (1994)

The purpose of this study was to examine factors predicting the development of posttraumatic stress symptoms after a traumatic event, the 1991 Oakland/Berkeley firestorm. The major predictive factors of interest were dissociative, anxiety, and loss of personal autonomy symptoms reported in the immediate aftermath of the fire; contact with the fire; and life stressors before and after the fire.Subjects were recruited from several sources so that they would vary in their extent of contact with the fire. Of 187 participants who completed self-report measures about their experiences in the aftermath of the firestorm, 154 completed a follow-up assessment. Of these 154 subjects, 97% completed the follow-up questionnaires 7-9 months after the fire. The questionnaires included measures of posttraumatic stress and life events since the fire.Dissociative and loss of personal autonomy symptoms experienced in the fire's immediate aftermath, as well as stressful life experiences occurring later, significantly predicted posttraumatic stress symptoms measured 7-9 months after the firestorm by a civilian version of the Mississippi Scale for Combat-Related Posttraumatic Stress Disorder and the Impact of Event Scale. Dissociative symptoms more strongly predicted posttraumatic symptoms than did anxiety and loss of personal autonomy symptoms. Intrusive thinking differs from other kinds of posttraumatic symptoms in being related directly to the trauma and previous stressful life events.These findings suggest that dissociative symptoms experienced in the immediate aftermath of a traumatic experience and subsequent stressful experiences are indicative of risk for the later development of posttraumatic stress symptoms. Such measures may be useful as screening procedures for identifying those most likely to need clinical care to help them work through their reactions to the traumatic event and to subsequent stressful experiences.
Staging for pediatric patients with Hodgkin's disease.
Authors: L R Prosnitz
Journal: Journal of Clinical Oncology (1988)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1988.6.1.179 Journal of Clinical Oncology - published online before print September 22, 2016 PMID: 3335890 Staging for pediatric patients with Hodgkin's disease. L R ProsnitzxL R ProsnitzSearch for articles by this author https://doi.org/10.1200/JCO.1988.6.1.179 PDF "Staging for pediatric patients with Hodgkin's disease.." Journal of Clinical Oncology, 6(1), pp. 179–180© 1988 by American Society of Clinical Oncology
Effect of Three Strains of BeG Against a Murine Leukemia After Drug Therapy
Authors: Neal A. Sher, John W. Pearson, Sotiros D. Chaparas, Michael A. Chirigos
Journal: JNCI Journal of the National Cancer Institute (1973)

Journal Article Effect of Three Strains of BeG Against a Murine Leukemia After Drug Therapy Get access Neal A. Sher, M.D., Neal A. Sher, M.D. 2Division of Bacterial Products, Bureau of Biologics, Food and Drug Administration, Building 29, Room 414, National Institutes of Health, Public Health Service, U.S. Department of Health, Education, and Welfare, Bethesda, Md. 20014 Search for other works by this author on: Oxford Academic PubMed Google Scholar John W. Pearson, Ph.D., John W. Pearson, Ph.D. 3Viral Biology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Md. 20014 Search for other works by this author on: Oxford Academic PubMed Google Scholar Sotiros D. Chaparas, Ph.D., Sotiros D. Chaparas, Ph.D. 2Division of Bacterial Products, Bureau of Biologics, Food and Drug Administration, Building 29, Room 414, National Institutes of Health, Public Health Service, U.S. Department of Health, Education, and Welfare, Bethesda, Md. 20014 Search for other works by this author on: Oxford Academic PubMed Google Scholar Michael A. Chirigos, Ph.D. Michael A. Chirigos, Ph.D. 3Viral Biology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Md. 20014 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 51, Issue 6, December 1973, Pages 2001–2003, https://doi.org/10.1093/jnci/51.6.2001 Published: 01 December 1973 Article history Received: 16 August 1973 Accepted: 30 August 1973 Published: 01 December 1973
Erratum to: Promoter-like epigenetic signatures in exons displaying cell type-specific splicing
Authors: Joao Curado, Camilla Iannone, Hagen Tilgner, Juan Valcárcel, Roderic Guigó
Journal: Genome biology (2016)

After the publication of this work [1] an error was noticed in Fig. 7. The panel ‘h’ is missing from Fig. 7. Please see the corrected figure below. The publisher apologises for this error.



Fig. 7

Relationship between promoter and ‘promoter-like’ exons. a Distribution of the distance (in nucleotides) between annotated TSS of ‘promoter-like’ and non-‘promoter-like’ exons. b Distribution of the distance ...
Abstract 20050: Impact of Median Household Income and Hospital Variation in the Utilization of Do-not-resuscitate Order in Cardiac Arrest: A National Perspective
Authors: Sopan Lahewala, Shantanu Solanki, Neil Patel, Nileshkumar J Patel, Achint Patel, Grishma Dhaduk, Chirag Bambhroliya, Darshan Patel, Shilpkumar Arora, Nilay Patel, Abhishek Deshmukh, Apurva Badheka, Umesh Gidwani, Theodore Schreiber, Cindy Grines
Journal: Circulation (2014)

Background: The factors determining DNR status in patients (pts) with cardiac arrest have not been well elucidated. Objective: The goal of our study was to assess impact of median household income and inter-hospital variation in utilization of DNR in Cardiac arrest. Methods: We queried the Healthcare Cost and Utilization Project’s Nationwide Inpatient Sample (NIS) database from 2011 using the ICD-9-CM code for cardiac arrest (427.5) as principal diagnosis. We defined pts’ DNR status with ICD code - V49.86 as a secondary diagnosis. Pts with age &lt; 18 were excluded. NIS represents 20% of all US hospital pts. We built a hierarchical two level model adjusted for multiple confounding factors. Discrimination power of models was assessed using c statistics. Inter class correlation (ICC) and Median Odds Ratio (MOR) were generated from the hierarchical model. Results: We identified 1854 pts (weighted: 8915) with cardiac arrest across 1854 hospitals in the US, out of which 1.87% pts (366 pts, weighted: 1755) opted for DNR. Pts with higher median household income had decreased utilization of DNR (OR, 95% CI, P-Value) in 4th quartile: 0.59, 0.45-0.78, p&lt;0.001, as compared to all other quartile. Also, with every 10 year increase in age, the rate of DNR increased (1.25, 1.18-1.32, p &lt; 0.001). There was no statistically significant difference in other variables such as female gender, weekend admission, insurance type, teaching status of the hospital or hospital volume. C-statistics of model to generate ICC and MOR was 0.90. ICC was 60.6, which indicates that approximately 60.6 % of variation in utilization of DNR was attributable to the behavior of individual hospitals, and MOR was 8.5 which indicates that a randomly selected patient receiving DNR at a particular hospital would have approximately 9-fold higher odds of receiving DNR than an identical patient at a different randomly selected hospital. Conclusion: Our study highlights vast variation in utilization of DNR in randomly selected 2 different hospitals with cardiac arrest pts. It also indicates a disparity in utilization of DNR orders in Pts with higher median household income as compared to lower household income.
T-cell prolymphocytic leukemia: 17-year experience at a single institution
Authors: F. Ravandi-Kashani, S. O'Brien, S. Lerner, A. Ferrajoli, W. Wierda, F. Giles, M. Herling, D. Jones, H. Kantarjian, M. Keating
Journal: Journal of Clinical Oncology (2004)

6570 Background: T-cell prolymphocytic leukemia (T-PLL) is a rare lymphoid malignancy commonly associated with an aggressive clinical course. Molecular characterization of recurrent chromosomal aberrations has led to the identification of the TCL1 locus at chromosome 14q32.1; the expression of this gene (increased as the result of rearrangements involving 14q32.1) appears to be of pathogenic significance. Although objective response rates up to 50% have been reported, the long-term outcome is generally poor. Therapy with alemtuzumab has been associated with an increased complete response (CR) rate and potentially improved outcome (Dearden CE, et al. Blood, 98, 1721). Methods: The available data on 57 patients with T-PLL seen at the UT-MDACC from 1986 to 2003 were reviewed. Pathology specimens were evaluated and other T-lymphoid malignancies were excluded. Results: The median age at presentation to MDACC was 63 years. The median white cell count, lymphocyte count, hemoglobin, and platelet count were 144 x 109/L, 70.3 x 109/L, 11.8 g/dL, and 85 x 109/L respectively. Patients had received up to 6 prior therapies. Treatment regimens at MDACC included fludarabine based regimens (n= 7), cladribine (n= 6), alemtuzumab (n= 18), arabinosyl guanine (n= 9), and other agents/combinations (n=7). Twenty-nine patients were positive for TCL1 expression, 11 patients were negative and TCL1 status was unknown in 17 patients. Response rates based on therapy and TCL1 expression are presented below. Overall response (OR) to alemtuzumab was significantly better than all other regimens (p=0.02). There was a trend for better OR for the TCL1 negative patients. Conclusions: Despite the availability of more promising agents, the prognosis in this rare disorder remains poor. Better characterization of the molecular events that are pathogenic in this disease may provide targets for therapeutic intervention. No significant financial relationships to disclose.
PTEN opposes negative selection and enables oncogenic transformation of pre-B cells
Authors: Seyedmehdi Shojaee, Lai N Chan, Maike Buchner, Valeria Cazzaniga, Kadriye Nehir Cosgun, Huimin Geng, Yi Hua Qiu, Marcus Dühren von Minden, Thomas Ernst, Andreas Hochhaus, Giovanni Cazzaniga, Ari Melnick, Steven M Kornblau, Thomas G Graeber, Hong Wu, Hassan Jumaa, Markus Müschen
Journal: Nature Medicine (2016)
Reply
Authors: Grace H. Lo, Timothy E. McAlindon, Jeffrey B. Driban, Gillian A. Hawker, Lori Lyn Price, Jing Song, Charles B. Eaton, Marc C. Hochberg, Rebecca D. Jackson, C. Kent Kwoh, Michael C. Nevitt, Dorothy D. Dunlop
Journal: Arthritis & Rheumatology (2016)
Multicentre study on inflammatory skin diseases from The International Confocal Working Group: specific confocal microscopy features and an algorithmic method of diagnosis
Authors: M. Ardigo, C. Longo, S. Gonzalez
Journal: British Journal of Dermatology (2016)

The real value of reflectance confocal microscopy (RCM) for the evaluation of inflammatory skin conditions remains unclear. A project on RCM for inflammatory skin diseases involving international centres was designed by a coordinating centre and executed under the supervision of the International Confocal Working Group. To identify specific confocal features useful for distinction between the three main groups of superficial inflammatory skin diseases. Nineteen different RCM features were evaluated in a total of 155 lesions, diagnosed as spongiotic (45), interface (52) or psoriasiform (58) dermatitis, collected by a consortium of 19 different centres. Univariate and multivariate analysis identified RCM descriptors for the three main superficial inflammatory disease groups. Later, a multivariate method was employed to define a scoring system to be applied on an algorithmic method of analysis for fast clinical application. Our preliminary evaluation supports the use of RCM for the identification of confocal patterns consistent with the major features of the diagnostic groups of inflammatory skin diseases. Moreover, an efficient multivariate method for clinical in vivo RCM diagnosis using a tree decision diagram has been established.
Fulvestrant (F) in metastatic breast cancer: Standard dose (Std) vs loading dose (Ld)—A retrospective study
Authors: C. D. Moussallem, A. Lopez, A. Gauthier, S. Moore, M. Johnson, J. L. Murray, N. K. Ibrahim
Journal: Journal of Clinical Oncology (2006)

10575 Background: Fulvestrant is shown to be an effective hormonal agent in menopausal hormone-receptor positive metastatic breast cancer (MBC) patients. This study aimed at showing if Ld of fulvestrant will improve its efficacy over the FDA approved Std schedule. Methods: We retrospectively reviewed our pharmacy electronic database over a period of two years to identify MBC patients who were treated with fulvestrant. Patients received either Std of 250 mg IM on day (d) 1 and repeated Q28d or Ld of 500 mg IM d1 and 15 and Std on d28 which was repeated every 28 days until evidence of progression. All medical records were reviewed and responses were recorded as improved disease (ID), stable disease (SD), or progressive (PD) as documented by the treating oncologist. Time to response (TTR) (the interval from first injection until response) as well the duration of response (DR), was determined. Results: Medical records of 157 consecutive, evaluable patients who received F for their MBC were identified and reviewed. Group 1 (Gp1) received std (N = 122) and Group 2 (Gp2) received loading dose (N = 35). There were no significant differences between the two groups in relation to age, pathology, grade, Her-2, ER and PR status or number of prior chemotherapy regimens (p &gt; 0.05). Gp2 had statistically significant more prior hormone therapies (p = 0.0159). Median number of doses for Gp2 was 5 (R: 1–18) compared to 3 (R: 1–25) for Gp1 (p = 0.0169). Responses (ID) 14% for Gp1 and 18% for Gp2; clinical benefits (ID + SD) were 37.7% and 38%, respectively, NSS (p = 0.9550). TTR was 10 (R: 6–32) wks for Gp1 and 8 (R: 4–20) wks for Gp2; the DR was 15.5 (R: 4- 84) weeks for Gp1, and 12 (R: 2- 96) for Gp2. No statistical significance was detected between the 2 groups. Conclusions: This study showed there is no significant difference between the 2 dose schedules, either in the response rate or its duration. Prospective studies are needed to prove the equivalence of the Std and Ld of F. No significant financial relationships to disclose.
Lung-Cancer Mortality as Related to Residence and Smoking Histories. I. White Males
Authors: W HAENSZEL, D B LOVELAND, M G SIRKEN
Journal: JNCI Journal of the National Cancer Institute (1962)

Journal Article Lung-Cancer Mortality as Related to Residence and Smoking Histories. I. White Males Get access William Haenszel, William Haenszel Search for other works by this author on: Oxford Academic PubMed Google Scholar Donald B. Loveland, Donald B. Loveland Search for other works by this author on: Oxford Academic PubMed Google Scholar Monroe G. Sirken Monroe G. Sirken Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 28, Issue 4, April 1962, Pages 947–1001, https://doi.org/10.1093/jnci/28.4.947 Published: 01 April 1962 Article history Received: 06 November 1961 Published: 01 April 1962